Novel sulfonated and phosphonated analogs of distamycin which inhibit the replication of HIV.
暂无分享,去创建一个
R. Kiser | A. Borgia | R. Schultz | D. Clanton | W. Rice | R. Buckheit | R Schultz | R W Buckheit | W G Rice | S. Terpening | D J Clanton | R Kiser | N Mongelli | S J Terpening | A L Borgia | V Narayanan | J P Bader | N. Mongelli | J. Bader | V. Narayanan
[1] O. Weislow,et al. Design, synthesis, and biological evaluation of cosalane, a novel anti-HIV agent which inhibits multiple features of virus reproduction. , 1994, Journal of medicinal chemistry.
[2] M. Cloyd,et al. Spectrum of biological properties of human immunodeficiency virus (HIV-1) isolates. , 1990, Virology.
[3] W. Rice,et al. The site of antiviral action of 3-nitrosobenzamide on the infectivity process of human immunodeficiency virus in human lymphocytes. , 1993, Proceedings of the National Academy of Sciences of the United States of America.
[4] F. Schabel,et al. Inhibition of gross leukemia virus-induced plaque formation in XC cells by 3-deazauridine. , 1974, Journal of the National Cancer Institute.
[5] O. Weislow,et al. Diarylsulfones, a new chemical class of nonnucleoside antiviral inhibitors of human immunodeficiency virus type 1 reverse transcriptase , 1993, Antimicrobial Agents and Chemotherapy.
[6] M. Boyd,et al. New soluble-formazan assay for HIV-1 cytopathic effects: application to high-flux screening of synthetic and natural products for AIDS-antiviral activity. , 1989, Journal of the National Cancer Institute.
[7] B. Haynes,et al. Frequent detection and isolation of cytopathic retroviruses (HTLV-III) from patients with AIDS and at risk for AIDS. , 1984, Science.
[8] S. Lagakos,et al. The Concorde trial , 1993, The Lancet.
[9] Philip R. Johnson,et al. An African primate lentivirus (SIVsmclosely related to HIV-2 , 1989, Nature.
[10] M. Prichard,et al. A three-dimensional model to analyze drug-drug interactions. , 1990, Antiviral research.
[11] M. Boyd,et al. A semiautomated multiparameter approach for anti-HIV drug screening. , 1991, Journal of virological methods.
[12] Paul Kellam,et al. Convergent combination therapy can select viable multidrug-resistant HIV-1 in vitro , 1993, Nature.
[13] J. Chermann,et al. Isolation of a T-lymphotropic retrovirus from a patient at risk for acquired immune deficiency syndrome (AIDS). , 1983, Science.
[14] J. Levy,et al. Isolation of lymphocytopathic retroviruses from San Francisco patients with AIDS. , 1984, Science.
[15] Jerome A. Zack,et al. HIV-1 entry into quiescent primary lymphocytes: Molecular analysis reveals a labile, latent viral structure , 1990, Cell.
[16] E. Gruszecka-Kowalik,et al. Quinobene, a new potent anti-HIV agent. , 1992, Biochemical and biophysical research communications.
[17] E A Emini,et al. Viral resistance to human immunodeficiency virus type 1-specific pyridinone reverse transcriptase inhibitors , 1991, Journal of virology.
[18] G. Pavlakis,et al. A bioassay for HIV-1 based on Env-CD4 interaction. , 1990, AIDS research and human retroviruses.
[19] Michael S. Saag,et al. A Short-Term Clinical Evaluation of L-697,661, a Non-Nucleoside Inhibitor of HIV-1 Reverse Transcriptase , 1993 .
[20] H. Mitsuya,et al. Anti-retroviral therapy of human immunodeficiency virus infection: current strategies and challenges for the future. , 1991, Blood.
[21] P. Nara,et al. Quantitative infectivity assay for HIV-1 and -2 , 1988, Nature.
[22] J. Louis,et al. Purification of HIV‐1 wild‐type protease and characterization of proteolytically inactive HIV‐1 protease mutants by pepstatin A affinity chromatography , 1991, FEBS letters.
[23] J. Levy,et al. Characterization of the AIDS-associated retrovirus reverse transcriptase and optimal conditions for its detection in virions. , 1985, Virology.
[24] M. Kozlowski,et al. Inhibition of gp120 Binding to the CD4 Antigen by Dyes: Mechanism of Effect and Contribution to anti-HIV Activity , 1992 .
[25] O. Weislow,et al. Sulfonic Acid Dyes: Inhibition of the Human Immunodeficiency Virus and Mechanism of Action , 1992, Journal of acquired immune deficiency syndromes.
[26] A. Fauci,et al. Differential effect of monoclonal anti-DR antibody on monocytes in antigen- and mitogen-stimulated responses: mechanism of inhibition and relationship to interleukin 1 secretion. , 1983, Cellular immunology.
[27] R. Swanstrom,et al. Characterization of an HIV-1 isolate displaying an apparent absence of virion-associated reverse transcriptase activity. , 1991, AIDS research and human retroviruses.
[28] B. Larder,et al. Novel mutation (V75T) in human immunodeficiency virus type 1 reverse transcriptase confers resistance to 2',3'-didehydro-2',3'-dideoxythymidine in cell culture , 1994, Antimicrobial Agents and Chemotherapy.
[29] M. Emerman,et al. Detection of replication-competent and pseudotyped human immunodeficiency virus with a sensitive cell line on the basis of activation of an integrated beta-galactosidase gene , 1992, Journal of virology.
[30] B. Larder,et al. Interactions between drug resistance mutations in human immunodeficiency virus type 1 reverse transcriptase. , 1994, The Journal of general virology.